Gao Li

Gao Li


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
YGYanbin Guan
Yanbin Guan
JHJiangeng Huang
Jiangeng Huang
LZLan Zuo
Lan Zuo
JXJiaqiang Xu
Jiaqiang Xu
LSLuqin Si
Luqin Si
GLGao Li
Gao Li

1 October 2010 in Current Medical Science
Verified
Journal Article
Closed access
PDF file
ZRZichao Rao
Zichao Rao
LSLuqin Si
Luqin Si
YGYanbin Guan
Yanbin Guan
HPHongping Pan
Hongping Pan
JQJun Qiu
Jun Qiu
GLGao Li
Gao Li

14 April 2011 in Journal of Pharmacy & Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
Abdullah K RabbaAbdullah K Rabba
Abdullah K Rabba
LSLuqin Si
Luqin Si
KXKewen Xue
Kewen Xue
MLMing Li
Ming Li
GLGao Li
Gao Li
PURPOSE: To determine experimentally the intestinal permeability of the anticancer prodrug irinotecan, and to quantify the amount of its cytotoxic metabolite SN-38 that is intestinally excreted (exsorped) as a predictor of intestinal toxicity, and to assess the effect of p-glycoprotein (p-gp) inhibitors (verapamil as a model) on the permeability and toxicity of irinotecan. METHODS: Single pass intestinal perfusion of rat’s whole length small intestines is applied to assess the permeability of the parent drug and quantify the intestinally excreted metabolite. The perfusion solution contained 30μg/ml of irinotecan (control group) without or with verapamil (verapamil group). A simple reversed phase HPLC method with UV detection is developed and validated for simultaneous determination of irinotecan and SN-38 using camptothecin as an internal standard. RESULTS: HPLC-UV method found to be simple, specific, accurate, and precise. Effective permeability coefficient of irinotecan found to be 4.9±1.7 10-3 mm/min and was doubled in verapamil group (P=0.007). Average cumulative amount of SN-38 exsorped found to be 29 ng/cm over 2 hours perfusion time which was decreased to 15 ng/cm in verapamil group (P=0.016). CONCLUSIONS: in situ intestinal perfusion method was successfully applied to quantify the permeability of irinotecan and the exsorption of SN-38 in the same experiment, in a manner that robustly reflects real in vivo situation. P-gp inhibition using verapamil found to significantly enhance the intestinal permeability of irinotecan and potentially decrease the intestinal toxicity due to SN-38 exposure. This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.